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hlthough our understanding and therapy of chronic heart
ailure have advanced substantially, acute decompensation
f heart failure remains a frequent cause of hospitalization
nd death (1,2). New effective treatments for acute decom-
ensated heart failure remain elusive despite several recent
andomized clinical trials of promising new drugs and
nterventions (3–5). Many hospitals have created heart
ailure units with standardized protocols to ensure that staff
roactively, and consistently, apply the best current treat-
ents and processes of care to appropriate patients to reduce
omplications and improve outcomes. Yet length of stay,
hort-term readmission rates, and mortality remain signifi-
ant (6), suggesting that our treatment paradigms are not
ddressing the core problems or precipitants.
See page 1803
The cascade of acute decompensated heart failure re-
uires new understanding and interventions. Its importance
nd impact are reflected in clinical trials in which a
eduction in hospital admission for worsening heart failure
s targeted as one of the most common clinical end points.
t remains a common reason for hospital admission in
atients older than 65 years and consumes many resources.
his is despite many large trials that have shown that heart
ailure can be prevented and that time to first heart failure
dmission can be reduced, although this may often be a
ostponement rather than a cure. Upstream, specialized
utpatient clinics have been established to stabilize chronic
eart failure and reduce decompensation. They have flour-
shed to some degree, but the expertise and care provided
re not standardized, although models are available (7–10).
hese clinics and individual physicians including primary
are emphasize evidence-based therapies (11–14), persis-
ence with prescribed treatments, avoidance of a dietary
odium load, and patient recognition of worsening symp-
oms as a trigger to increase diuretic dose according to
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.p
From University Hospital, London Health Sciences Centre, London, Ontario,
anada. Dr. Arnold is on the advisory board for Medtronic.revious education and specific directions, including contact
ith their physician if symptoms do not promptly improve.
any patients are helped in this way, but others still have
cute decompensation without recognizing precipitants or
arning signs. Weight changes may not be measured
egularly or may be a later sign of peripheral edema rather
han an early sign of pulmonary congestion. The patient
ften recognizes the problem late, and a more sensitive
ndicator of early and persistent accumulation of pulmonary
ongestion could reduce clinical decompensation with fewer
rgent physician visits and hospital admissions.
The emerging emphasis on device therapy in heart failure
atients provides additional unique opportunities to study
nd intervene in the management of this high-risk popula-
ion. Implantable cardioverter-defibrillators (ICDs) reduce
he 5-year mortality rate by 23% among heart failure
atients with poor left ventricular function (15,16) and
30% among those with previous cardiac arrest (17–20).
ardiac resynchronization therapy (CRT) (biventricular
acing) coordinates ventricular contraction in a wide QRS
hythm and can reduce heart failure symptoms (21–23),
mprove quality of life, and reduce hospital admissions for
eart failure (24,25). As a result, ICD/CRT therapy for
eart failure patients has grown rapidly. It has also provided
n exciting opportunity to expand continuous monitoring
eyond cardiac rhythm to include novel surrogate measures
f lung congestion such as intrathoracic impedance between
he lead tip in the right ventricle and the generator in the
eft subcutaneous infraclavicular region. An increase in lung
ater is reflected as a decrease in measured impedance, and
his may be detected and reported by the device before
ymptoms of heart failure occur. Impedance monitoring is
easible, and established device algorithms and thresholds
orrelate reasonably well with invasive measures of venous
ressure (26) and have demonstrated modest sensitivity and
pecificity for clinical events (27). Among patients at high
isk of fluid overload and heart failure exacerbations, early
arning of impending decompensation may allow treatment
djustment even before symptoms occur and may have an
mpact on important clinical outcomes such as heart failure
ospitalization (28). Although promising, intrathoracic im-
edance measures are confounded by extrapulmonary
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The Art and Science of Heart Failure April 27, 2010:1811–3hanges in chest impedance, they demonstrate a less than
deal predictive value for heart failure exacerbations, and it is
ot yet fully clear what independent value they will provide
or heart failure management.
In an effort to improve the predictive value of these
mpedance measures, Whellan et al. (29), in this issue of the
ournal, devised an algorithm that combined impedance
ata with prospectively identified criteria: a fluid index
100  days or any 2 of the following criteria met during
evaluation period: long atrial fibrillation duration, rapid
entricular rate during atrial fibrillation, a high (60) fluid
ndex, low patient activity, high night heart rate, low heart
ate variability, low CRT pacing, or ICD shocks. The use of
ultiple parameters in this observational study significantly
mproved the ability to identify patients at risk of heart
ailure events, beyond the use of intrathoracic impedance
lone, in the subsequent 30 days. Although observational
tudies are important to develop testable hypotheses, they
annot replace randomized clinical trials to confirm the true
tility of this strategy. Whether additional parameters
eyond atrial fibrillation episodes, patient activity level, and
eart rate variability with the impedance fluid index will
ive increased predictive accuracy can be tested, but the
omposite score using the available described data is rational
nd sensible, and this study demonstrates some benefit with
his approach.
New prospective studies will expand our current knowl-
dge and refine diagnostic algorithms to predict heart failure
xacerbations. Thoracic impedance will be a strategy to
onsider in appropriate patients who require an ICD/CRT,
ut it would not be a primary impetus in the decision to
mplant such device therapy. Yet, it could become a valuable
ool to educate patients by correlating their impedance
easurements and other algorithm data with diet or med-
cation changes as well as by providing remote monitoring
or patients unable to attend regular outpatient visits.
urther studies are needed to refine algorithms, to study
eart failure with preserved ejection fraction, and to deter-
ine cost-effectiveness. Patient selection may evolve from
hose at highest risk to those at lower risk for whom
CD/CRT may not yet be indicated, and the incremental
alue of stand-alone impedance measures will need evidence
nd justification. The addition of other clinical data may
dd value to the currently described algorithm.
Hospital admissions for acute decompensated heart fail-
re are unplanned but are associated with significant mor-
idity and mortality. The opportunity to predict what often
eems currently unpredictable offers hope for patients,
hysicians, and payers.
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